Prevention and treatment of hypergastrinemia
    2.
    发明申请
    Prevention and treatment of hypergastrinemia 审中-公开
    预防和治疗高胃泌素血症

    公开(公告)号:US20050187152A1

    公开(公告)日:2005-08-25

    申请号:US10829137

    申请日:2004-04-21

    摘要: Serum-associated hypergastrinemia is treated by administration of gastrin active or passive immunization. An anti-gastrin immunogenic composition containing a gastrin G17 or G34 peptide fragment which is amino acid spacer-linked to an immunogenic carrier, is administered so as to effectively neutralize the circulating gastrin hormone, and moreover, inhibit autocrine activity by progastrin such as Gly-extended G17, and amidated G17, in patients with pernicious anemia. Moreover, the method includes administration of a therapeutically effective amount of anti-G17 or anti-G34 antibodies which may be in humanized form. Finally, the method provides ameliorating treatment of hypergastrinemic effects of proton pump inhibitors or H2 histamine receptor blocking agents or antagonists, in addition to treatment of hypergastrinemia caused by diseases such as pernicious anemia.

    摘要翻译: 通过施用胃泌素活性或被动免疫来治疗血清相关性高胃泌素血症。 给予含有与免疫原性载体间隔连接的氨基酸的胃泌素G17或G34肽片段的抗胃泌素免疫原性组合物,以有效中和循环的胃泌素激素,此外,抑制前胃泌素如Gly- 延长G17,并与G17阴性,患有恶性贫血患者。 此外,该方法包括施用治疗有效量的可以以人源化形式存在的抗G17或抗G34抗体。 最后,除了治疗由诸如恶性贫血等疾病引起的胃泌素血症外,该方法还提供改善质子泵抑制剂或H 2 H 2组胺受体阻断剂或拮抗剂的高胃肠道作用的改善。